Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking

We applied LIBRA-seq with ligand blocking to PBMC samples from donors that recovered from SARS-CoV-2 to identify the following paired heavy/light chain antibody sequences. Generally, SARS-CoV-2 therapeutic antibody discovery efforts have met with notable success but have been associated with a generally inefficient process, requiring the production and characterization of exceptionally large numbers of candidates for the identification of a small set of leads. In this work, we show that incorporating antibody-ligand blocking as part of LIBRA-seq, the high-throughput sequencing platform for antibody discovery, resulted in efficient identification of ultra-potent neutralizing antibodies against SARS-CoV-2.